middle.news
Acrux gains FDA clarity for female testosterone spray trials
9:39am on Monday 19th of October, 2026 AEDT
•
Pharmaceuticals
Read Story
Acrux gains FDA clarity for female testosterone spray trials
9:39am on Monday 19th of October, 2026 AEDT
Key Points
FDA confirms Phase III pathway for Female Testosterone MDTS
Potential three-year data exclusivity on approval submission
$1.977 million FY26 R&D tax incentive rebate received
$226,000 reported net operating cash inflow for the quarter
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Acrux (ASX:ACR)
OPEN ARTICLE